There is no fulltext present in this item.

Find Full text  
Title: Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial
Author(s): Korjian, S.; Braunwald, Eugene; Daaboul, Y.; Verheugt, F.W.A. ; Bode, C.; Tendera, M.; Burton, Paul; Gibson, C. Michael
Publication year: 2019
Source: European Heart Journal Acute Cardiovascular Care, vol. 8, iss. 2, (2019), pp. 186-193
ISSN: 2048-8726
DOI: https://doi.org/10.1177/2048872617745003
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/202137   https://hdl.handle.net/2066/202137

Display more details
Subject: All institutes and research themes of the Radboud University Medical Center
Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences
Organization: Cardiology
Journal title:
European Heart Journal Acute Cardiovascular Care
Volume: vol. 8
Issue: iss. 2
Page start: p. 186
Page end: p. 193

This item appears in the following Collection(s)

Browse

Statistics